ERS International Congress 2021: Highlights from the Pediatric Assembly

This article was originally published here

ERJ Open Res. 2022 May 23;8(2):00643-2021. doi: 10.1183/23120541.00643-2021. eCollection 2022 Apr.

ABSTRACT

In this review, Early Career Members of the European Respiratory Society (ERS) and Chairs of ERS Assembly 7: Paediatrics present pediatric respiratory medicine highlights from the ERS International Congress 2021. The eight scientific groups of This assembly covers respiratory physiology and sleep, asthma and allergy, cystic fibrosis (CF), respiratory infection and immunology, neonatology and intensive care, respiratory epidemiology, bronchology and lung and airway development. Here we describe new developments in lung function testing and diagnosis of sleep-disordered breathing, early exposures affecting lung function in children, and the effects of COVID-19 on sleep and lung function. In pediatric asthma, we present the important role of the exposome in asthma development and how biologics can provide better outcomes. We discuss new methods to assess the distal airways in children with cystic fibrosis, as some details remain blind when using the pulmonary clearance index. Additionally, we summarize new ERS guidelines for the management of bronchiectasis in children and adolescents. We present interventions to reduce morbidity and monitor lung function in neonates at risk for bronchopulmonary dysplasia and long-term chronic respiratory morbidity from this disease. In respiratory epidemiology, we characterize primary ciliary dyskinesia, identify early determinants of respiratory health, and describe the effect of COVID-19 preventive measures on respiratory symptoms. We also describe the epidemiology of interstitial lung disease, the possible consequences of tracheomalacia, and a classification of diffuse alveolar hemorrhage in children. Finally, we emphasize that the characterization of genes and pathways involved in the development of a disease is essential to identify new biomarkers and therapeutic targets.

PMID:35615416 | PMC: PMC9125040 | DOI:10.1183/23120541.00643-2021


Source link

Comments are closed.